| Document |
Document Title |
|
WO/2019/180646A1 |
The present technology provides triazolone derivatives or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and the use thereof. The triazolone derivatives or their...
|
|
WO/2019/183527A1 |
Disclosed herein are compounds capable of inducing apoptosis through promoting Nur77 interaction with Bcl-2 and through modulating mitochondrial activities. Also disclosed herein are compositions and methods using these compounds and com...
|
|
WO/2019/176754A1 |
The present invention provides: a photoelectric conversion element which has a photoelectric conversion film that has a narrow half width of the absorption peak; an imaging element; an optical sensor; and a compound. A photoelectric conv...
|
|
WO/2019/170745A1 |
The present invention relates to compounds of Formula (I), wherein R1, R2, R3, R4 and G are as defined herein. The invention further relates to herbicidal compositions which comprise a compound of Formula (I), to their use for controllin...
|
|
WO/2019/173437A1 |
Disclosed are compounds of formulas (I) and (III) for treating or preventing a disease or disorder responsive to activation of a D1 dopamine receptor agonist in a mammal in need thereof, wherein R1 R6 and R11 R13 are as defined herein. E...
|
|
WO/2019/173761A1 |
Disclosed herein are embodiments of a compound that inhibits c-Abl tyrosine kinase (also referred to herein as "c-Abl"). The compound embodiments described herein are novel c-Abl inhibitors that can bind to c-Abl at an allosteric site an...
|
|
WO/2019/172649A1 |
The present application relates to a compound of chemical formula 1 and an organic light emitting element comprising same.
|
|
WO/2019/170572A1 |
The present invention relates to compounds of the formula (1) which are suitable for use in electronic devices, in particular organic electroluminescent devices, and to electronic devices which comprise these compounds.
|
|
WO/2019/173182A1 |
The disclosure relates to compounds of Formula (II), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for ...
|
|
WO/2019/171174A2 |
This disclosure provides, among other things, compositions comprising quantities of oltipraz, either in recrystallized or formulated crystal form, and a composition that reduces the rate of cellular oxygen consumption such as atovaquone,...
|
|
WO/2019/172830A1 |
The present disclosure concerns use of compounds of formula I, or salts thereof, as reactive matrices for desorption and laser ablation ionization spectrometry. The disclosure further concerns compounds of formula II, or salts thereof, a...
|
|
WO/2019/170904A1 |
The present invention relates to a compound according to general formula (I) which acts as a modulator of FPR2 and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by FPR2.
|
|
WO/2019/166619A1 |
The present invention relates to sulfonylureas and sulfonylthioureas of formula (I) comprising a 5-membered heteroaryl ring attached to the sulfonyl group, wherein the heteroaryl ring is di-substituted at the 3- and 4- positions relative...
|
|
WO/2019/169183A1 |
The present disclosure provides various compounds, compositions, and methods of BACE inhibition that interact with both BACE and APP to increase selectivity of the inhibitor. Compounds presented herein exhibit desirably low IC50 values a...
|
|
WO/2019/166475A1 |
The present invention relates to synthetic receptors for ionophoric compounds, such as ionophoric toxins. Hence, the invention provides synthetic molecules capable of binding different ionophoric compounds, thereby being suitable for use...
|
|
WO/2019/166305A1 |
The invention relates to benzoyl amides of general formula (I), as herbicides. In formula (I), B represents N or X1 and X2 represent O or S(O)n. R, Ra, Rb, Rc, Rd, Re, Rf and Rx represent radicals such as hydrogen, fluorine, chlorine, hy...
|
|
WO/2019/168140A1 |
Provided are an amide compound represented by general formula [I] or a salt thereof, an agricultural and horticultural microbicide containing the amide compound or a salt thereof as an active ingredient, and a method of using the agricul...
|
|
WO/2019/166629A1 |
The present invention relates to compounds of formula (I) wherein Q is selected from O or S; R1 is a saturated or unsaturated, optionally substituted hydrocarbyl group optionally including one or more heteroatoms N, O or S; R2 is a cycli...
|
|
WO/2019/167863A1 |
The present invention relates to: a compound represented by formula (I), which has excellent insecticidal activity, miticidal activity and/or nematicidal activity, while having excellent safety, and which is able to be synthesized indust...
|
|
WO/2019/166578A1 |
The present invention relates to the field of catalytic hydrogenation and to the use of ruthenium complexes having a bidentate diphosphine ligand or two monodentate phosphine ligands, two carboxylate ligands and optionally a diamine liga...
|
|
WO/2019/162458A1 |
The present invention relates to novel compounds which are particularly useful as inhibitors of bacterial glutaminyl cyclases (bacQC); pharmaceutical compositions comprising such compounds; compounds and/or pharmaceutical compositions fo...
|
|
WO/2019/162323A1 |
The present invention encompasses compounds of formula (I) (I), wherein the groups R1 to R5 have the meanings given in the claims and specification, their use as inhibitors of mutant EGFR, pharmaceutical compositions which contain compou...
|
|
WO/2019/162702A1 |
There is provided herein a compound of formula (I) wherein R1, R2, n, X, Q, L, m, R3 and p are as defined herein, which compounds are useful in the treatment of treatment of diseases characterised by impaired signalling of neurotrophins ...
|
|
WO/2019/163826A1 |
This compound is represented by formula (1) (X1 represents O or S; and at least two of Y1, Y2 and Y3 are N, except the case where ―Ar1―Ar2 and/or ―Ar3―Ar4 is a p-terphenyl-3-yl group.).
|
|
WO/2019/164054A1 |
The present invention provides a novel organic semiconductor compound, a method for manufacturing same, and an organic electronic element using same. The novel organic semiconductor compound of the present invention has a halo-substitute...
|
|
WO/2019/164301A1 |
The present specification provides a compound of chemical formula 1 and an organic light emitting diode comprising same.
|
|
WO/2019/164218A1 |
The present specification provides a compound of chemical formula 1 and an organic light emitting diode comprising same.
|
|
WO/2019/161157A1 |
Provided are compounds of Formula (I): and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with histone acetyltransferase (HAT).
|
|
WO/2019/157020A1 |
In one aspect, the disclosure relates to relates to substituted benzothiophene analogs which are useful as selective degraders of estrogen receptor, methods of making same, pharmaceutical compositions comprising same, and methods of trea...
|
|
WO/2019/156903A1 |
Disclosed are compounds of Formula 1, wherein J is and R1a, R1b, R2, R3, R4, R5, R6, R7, R8, R14, R15, R16, Q and X are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 and methods for c...
|
|
WO/2019/154663A1 |
The present invention relates to the use of compounds of formula I, wherein the variables are defined as given in the description and claims. The invention further relates to the compounds I and composition for compounds of formula I.
|
|
WO/2019/157417A1 |
Disclosed are compounds of formulas (I)-(IX) for treating or preventing a disease or disorder responsive to antagonism of a P2Y14R receptor agonist in a mammal in need thereof, wherein R1-R8, X, Y, Z, X', Y', Z', and A are as defined her...
|
|
WO/2019/154949A1 |
The present invention relates to a new class of fused thiophene derivatives and their uses for treating diseases such as infection, cancer, metabolic diseases, cardiovascular diseases, iron storage disorders and inflammatory disorders.
|
|
WO/2019/154366A1 |
Disclosed are a compound as shown in formula (I) or a salt thereof and the use thereof as potassium-competitive acid blockers or gastric acid secretion inhibitors. The compound has an inhibitory effect on a proton pump -H+/K+-ATPase, and...
|
|
WO/2019/154950A1 |
The present invention relates to a new class of fused thiophene derivatives and their uses for treating diseases such as infection, cancer, metabolic diseases, cardiovascular diseases, iron storage disorders and inflammatory disorders.
|
|
WO/2019/151682A1 |
The present invention provides a novel compound capable of improving luminous efficiency, stability, and lifespan of a device, an organic electric device using same, and an electronic device thereof.
|
|
WO/2019/152536A1 |
The present disclosure relates to compounds that are capable of modulating the WNT/Beta-Catenin pathway. The disclosure further relates to methods of treating colorectal cancer and other WNT/Beta-Catenin mediated cancers.
|
|
WO/2019/150220A1 |
The present invention relates to novel anthranilamides of Formula I, wherein, the definition of W1, W2, B1, B2, D, Z1, E, R1, R3, R4, m is as described in the description. The present invention also relates to the composition, combinatio...
|
|
WO/2019/149062A1 |
The present invention provides an aromatic amine compound with a structure as shown in general formula 1 for improving the light extraction efficiency and color purity of an organic light-emitting element, an organic light-emitting eleme...
|
|
WO/2019/150383A1 |
The present invention discloses an improved process for preparation of Luliconazole in high yield and purity involving a novel intermediate i.e., (S)- 2,4-Dichloro-alpha-(chloro methyl)benzene methanol 4-chlorosulfonyl chloride.
|
|
WO/2019/151318A1 |
Provided is an electro-optic polymer including an electro-optical molecule in which a π electron donor and a π electron acceptor are conjugated via a π conjugate bridge, and a base polymer, wherein an electro-optical coefficient (EO c...
|
|
WO/2019/149183A1 |
Disclosed are a biaryl derivative having a structure represented by Formula (I) and inhibitory activity against PD-1/PD-L1 interaction, a preparation method thereof, and a pharmaceutical application thereof. The series of compounds of th...
|
|
WO/2019/149959A1 |
This invention relates to novel compounds according to Formula (I) which are inhibitors of ghrelin O-acyltransferase (GOAT), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy ...
|
|
WO/2019/149919A1 |
The present invention relates to aminopropoxyphenylpiperidinylamidoderivatives having dual pharmacological activity towards both the α2δ subunit, in particular the α2δ-1 subunit, of the voltage-gated calcium channel and the µ-opioid...
|
|
WO/2019/150161A1 |
The present invention relates to compounds and drugs for the prophylaxis and treatment of leishmaniasis and Chagas disease, diseases caused by the parasites Leishmania panamensis and Trypanosoma cruzi. Two specific chemical inhibitors ag...
|
|
WO/2019/091434A9 |
Applications of an adenosine receptor agonist in the preparation of drugs for treating uresis dysfunctions of bladders of mammals, and a method for evaluating the adenosine receptor agonist in regulation of uresis dysfunctions of the bla...
|
|
WO/2019/148150A1 |
The present application provides bifunctional compounds of Formula X or an enantiomer, diastereomer, or stereoisomer thereof, or pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, which act as protein degradation ind...
|
|
WO/2019/147074A1 |
The present invention provides a novel heterocyclic compound and an organic light emitting device using the same.
|
|
WO/2019/146773A1 |
The present invention relates to a thiophene derivative represented by general formula (I) (wherein each symbol is as defined in the description) or a salt thereof, which has an activity to prevent the production of TNF-α and an activit...
|
|
WO/2019/147987A1 |
This invention is directed to antimicrobial compositions and methods of using the same to treat or prevent infection. A method of treating microbial infection in a subject, the method comprising administering to the subject a therapeutic...
|
